Acular patent ruling
Executive Summary
Federal appeals court rules in favor of Apotex in litigation over a patent covering Allergan's Acular (ketorolac ophthalmic solution). The appeals court on May 18 remanded the case to San Francisco federal court for further consideration on obviousness claims. In January 2004, the California court ruled that Allergan/Syntex' patent was valid and Apotex' ANDA infringed (1"The Pink Sheet" Jan. 19, 2004, In Brief)...
You may also be interested in...
Allergan prevails in Acular litigation
Apotex barred from introducing its generic version of the ocular inflammatory agent Acular (ketorolac ophthalmic solution) until 2009 after a San Francisco federal judge upholds the validity of an Allergan/ Syntex patent and finds Apotex' ANDA infringed. Apotex subsequently dismissed separate antitrust claims that hinge on the patent case. Apotex said it will appeal the patent ruling and could refile the anticompetition claims. FTC inquiry into Allergan's conduct with regard to Acular generics is ongoing (1"The Pink Sheet" Aug. 18, 2003, p. 14)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.